Skip to main content

Advertisement

SpringerLink
Log in

Modified escalated BEACOPP as salvage chemotherapy in classic Hodgkin lymphoma

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barlett N. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program. 2005;1:246.

    Google Scholar 

  2. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann Oncol. 1997;8(2):143–8.

    Article  CAS  PubMed  Google Scholar 

  3. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.

    Article  PubMed  Google Scholar 

  4. Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma. 2009;50(11):1803–8.

    Article  CAS  PubMed  Google Scholar 

  5. Eichenauer DA, Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? Leuk Lymphoma. 2009;50(11):1733–4.

    Article  CAS  PubMed  Google Scholar 

  6. Josting A, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002;20(1):221–30.

    Article  PubMed  Google Scholar 

  7. Lie AKW, Hui CH, Rawling T, Dyson PG, Thorp D, Benic J, et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant. 1998;22:853–7.

    Article  CAS  PubMed  Google Scholar 

  8. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, et al. A phase II study of plerixafor (AMD 3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1253–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No financial support.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology and Medical Oncology, Saint Louis University Cancer Center, 3655 Vista Avenue, West Pavilion, Saint Louis, MO, 63110, USA

    Mark J. Fesler & Paul J. Petruska

  2. Department of Radiology, Division of Nuclear Medicine, Saint Louis University Hospital, Saint Louis, USA

    Nghi C. Nguyen

Authors
  1. Mark J. Fesler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nghi C. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul J. Petruska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark J. Fesler.

About this article

Cite this article

Fesler, M.J., Nguyen, N.C. & Petruska, P.J. Modified escalated BEACOPP as salvage chemotherapy in classic Hodgkin lymphoma. Int J Hematol 92, 211–213 (2010). https://doi.org/10.1007/s12185-010-0630-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0630-9

Keywords

Search

Navigation